17-8173443-C-A
Position:
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BP4_ModerateBS1BS2
The NM_183065.4(TMEM107):c.*760G>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00236 in 761,446 control chromosomes in the GnomAD database, including 11 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.0063 ( 10 hom., cov: 33)
Exomes 𝑓: 0.0014 ( 1 hom. )
Consequence
TMEM107
NM_183065.4 3_prime_UTR
NM_183065.4 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 3.23
Genes affected
TMEM107 (HGNC:28128): (transmembrane protein 107) This gene encodes a transmembrane protein and component of the primary cilia transition zone. The encoded protein regulates ciliogenesis and ciliary protein composition. Human fibroblasts expressing a mutant allele of this gene exhibit reduced numbers of cilia, altered cilia length, and impaired sonic hedgehog signaling. In human patients, different mutations in this gene cause different ciliopathies, including Meckel-Gruber syndrome and orofaciodigital syndrome. [provided by RefSeq, May 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -10 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.22).
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00628 (956/152262) while in subpopulation AFR AF= 0.0199 (825/41554). AF 95% confidence interval is 0.0187. There are 10 homozygotes in gnomad4. There are 430 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 10 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TMEM107 | NM_183065.4 | c.*760G>T | 3_prime_UTR_variant | 5/5 | ENST00000437139.7 | NP_898888.1 | ||
SNORD118 | NR_033294.2 | downstream_gene_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TMEM107 | ENST00000437139.7 | c.*760G>T | 3_prime_UTR_variant | 5/5 | 1 | NM_183065.4 | ENSP00000402732 | P1 | ||
TMEM107 | ENST00000449985.6 | c.*809G>T | 3_prime_UTR_variant | 2/2 | 1 | ENSP00000404753 | ||||
SNORD118 | ENST00000363593.1 | downstream_gene_variant |
Frequencies
GnomAD3 genomes AF: 0.00626 AC: 953AN: 152146Hom.: 10 Cov.: 33
GnomAD3 genomes
AF:
AC:
953
AN:
152146
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00200 AC: 462AN: 231110Hom.: 3 AF XY: 0.00159 AC XY: 203AN XY: 127526
GnomAD3 exomes
AF:
AC:
462
AN:
231110
Hom.:
AF XY:
AC XY:
203
AN XY:
127526
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00139 AC: 844AN: 609184Hom.: 1 Cov.: 0 AF XY: 0.00123 AC XY: 409AN XY: 332932
GnomAD4 exome
AF:
AC:
844
AN:
609184
Hom.:
Cov.:
0
AF XY:
AC XY:
409
AN XY:
332932
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00628 AC: 956AN: 152262Hom.: 10 Cov.: 33 AF XY: 0.00578 AC XY: 430AN XY: 74452
GnomAD4 genome
AF:
AC:
956
AN:
152262
Hom.:
Cov.:
33
AF XY:
AC XY:
430
AN XY:
74452
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Pathogenic:1Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Leukoencephalopathy with calcifications and cysts Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine | Apr 06, 2020 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
TMEM107-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 16, 2024 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | SNORD118: BS1, BS2; TMEM107: BS1, BS2 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at